Remember when hospitals were supposed to cure patients, not investors’ headaches? Well, Shalby’s Q1 was a mix of firsts, hiccups, and geopolitics worthy of a Netflix drama. They finally crossed ₹300 crore quarterly revenue — history made! But like every good Indian cricket match, just when you thought victory was here, margins fell sick and PAT needed ICU care. Throw in Sanar Hospital’s Middle East patient drought, and suddenly “occupancy” sounds like hotel management, not healthcare. Stick around — the implant biz is dancing, the CFO is preaching debt discipline, and management promises 85% occupancy like a Bollywood climax twist.
2. At a Glance
Revenue up 5% YoY – Crossed ₹300 crore, CFO said it’s history, not Excel fraud.
EBITDA down 12% YoY – Apparently, anesthesia wore off too soon.
Margins fell to 16% (vs 19%) – Like weight loss without dieting.
PAT at ₹7.7 cr vs ₹14.7 cr YoY – Profits playing hide-and-seek.
Stock? Flat traders – Heard “double-digit growth” and muted the call.
3. Management’s Key Commentary
“First time in history we crossed ₹300 crore revenue.” (Translation: Pop the champagne… but don’t ask about profit margins.)
“EBITDA grew 85% QoQ but fell 12% YoY.” (Translation: We recovered from last quarter’s coma, but still weaker than last year’s diet.)
“Occupancy was 45% due to doctor exits and Middle East war.” (Translation: Patients didn’t come, doctors left, and apparently Gaza now runs our hospital P&L.)
“Average length of stay fell, ARPOB rose.” (Translation: Get patients out fast, bill them more — Shalby’s version of “Zara Hatke Zara Bachke.”)
“Shalby MedTech revenue up 74%, standalone EBITDA positive.” (Translation: Finally, implants making money instead of just X-ray selfies.)
“We expect 12-15% top line growth in FY26 with better margins.” (Translation: If optimism were revenue, we’d beat Apollo already.)
4. Numbers Decoded
Metric
Value Q1 FY26
YoY Change
One-Line Analysis
Revenue – The Hero
₹303 cr
+5%
Crossed ₹300 cr for first time; applause pls.
EBITDA – The Sidekick
₹48.5 cr
-12%
Still limping after last year’s glory run.
Margins – The Drama Qn
16%
-3% pts
Needs therapy; blames supply chain + low occ.
PAT – The Vanishing Act
₹7.7 cr
-47%
From ₹14.7 cr to 7.7 cr — magician’s trick.
Hospitals Revenue
₹242 cr
Flat
Domestic steady, Sanar coughing international.
MedTech Revenue
₹30.8 cr
+74%
Finally flexing implants muscle.
In short: Hospitals stable, MedTech sprinting, consolidated profits still wheezing on oxygen.
5. Analyst Questions
Neel Shah asked about lower ALOS. Mgmt: “Shorter stays boost ARPOB.” (Translation: Fast in, fast out — like Swiggy.)
